{"title":"[The significance and advancements of circulating tumor DNA in the diagnosis and treatment of operable non-small cell lung cancer].","authors":"Z F Li, Y He, K Z Chen","doi":"10.3760/cma.j.cn112139-20240627-00315","DOIUrl":null,"url":null,"abstract":"<p><p>Non-small cell lung cancer, characterized by high incidence and mortality rates, significantly threatens human health. Precisely assessing patient prognosis and implementing adaptive treatment strategies have emerged as pivotal issues in contemporary thoracic oncology. Postoperative minimal residual disease (MRD) detection through liquid biopsy has demonstrated substantial potential. Circulating tumor DNA (ctDNA) enables real-time dynamic monitoring of tumor alterations. With advancements in ctDNA detection technologies, ctDNA has become a core method for MRD assessment. In the context of postoperative surveillance, ctDNA detection facilitates more accurate prognostic stratification and early prediction of tumor recurrence. Regarding therapeutic interventions, ctDNA detection can predict the efficacy of neoadjuvant and adjuvant therapies. In the future, further elucidating the value of assessing ctDNA status in predicting patient prognosis and guiding drug therapies will contribute to the advancement of precision medicine and adaptive treatments.</p>","PeriodicalId":60685,"journal":{"name":"中华外科杂志","volume":"63 2","pages":"171-176"},"PeriodicalIF":0.0000,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"中华外科杂志","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.3760/cma.j.cn112139-20240627-00315","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0
Abstract
Non-small cell lung cancer, characterized by high incidence and mortality rates, significantly threatens human health. Precisely assessing patient prognosis and implementing adaptive treatment strategies have emerged as pivotal issues in contemporary thoracic oncology. Postoperative minimal residual disease (MRD) detection through liquid biopsy has demonstrated substantial potential. Circulating tumor DNA (ctDNA) enables real-time dynamic monitoring of tumor alterations. With advancements in ctDNA detection technologies, ctDNA has become a core method for MRD assessment. In the context of postoperative surveillance, ctDNA detection facilitates more accurate prognostic stratification and early prediction of tumor recurrence. Regarding therapeutic interventions, ctDNA detection can predict the efficacy of neoadjuvant and adjuvant therapies. In the future, further elucidating the value of assessing ctDNA status in predicting patient prognosis and guiding drug therapies will contribute to the advancement of precision medicine and adaptive treatments.
期刊介绍：
Chinese Journal of Surgery|Chin J Surg (monthly) is a high-level medical science and technology journal approved by the General Administration of Press and Publication of the People's Republic of China, under the supervision of the China Association for Science and Technology, and organised by the Chinese Medical Association for domestic and international public circulation. It was founded in January 1951, and is published on the basis of the Journal of Chinese Surgery. The Journal is aimed at senior and intermediate surgeons and related researchers, mainly reporting the leading scientific research results and clinical experience in the field of surgery, as well as the basic theoretical research that has a guiding effect on the clinical work of surgery.
Chinese Journal of Surgery|Chin J Surg is committed to reflecting the major research progress in the field of surgery in China and promoting academic exchanges at home and abroad. The main columns include thesis, meta-analysis, review, expert forum, synthesis, case report, diagnosis and treatment experience, technical exchange, clinical case discussion, academic controversy, and special lectures, etc. The journal has been accepted by the National Academy of Medicine of the United States. The journal has been included in many famous databases at home and abroad, such as the Biomedical Analysis and Online Retrieval System (MEDLINE) of the U.S. National Library of Medicine.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
